Soleno Therapeutics, Inc. (NASDAQ: SLNO) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $74.00 price target on the stock.
Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results [Yahoo! Finance]
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
Aardvark prices $94.2m IPO to fund development of Prader-Willi syndrome drug [Yahoo! Finance]